News Daily News Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab Michael O'Riordan February 05, 2025
News Daily News Use of Secondary CVD Prevention Meds Still Meager Worldwide Caitlin E. Cox February 03, 2025
News Daily News Aspirin Use for Primary Prevention Declining in US: NHANES Michael O'Riordan January 24, 2025
News Daily News Intra-arterial Lytics Don’t Help After Stroke Thrombectomy, but Questions Persist Todd Neale January 15, 2025
News Daily News Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments Michael O'Riordan January 03, 2025
News Daily News Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD Todd Neale December 06, 2024
News Conference News AHA 2024 Indian Patients Do Well on Dual-Combination Pills for Hypertension: TOPSPIN Caitlin E. Cox November 22, 2024
News Conference News AHA 2024 ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS Michael O'Riordan November 21, 2024
News Conference News AHA 2024 Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III Caitlin E. Cox November 21, 2024
News Conference News AHA 2024 Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF Shelley Wood November 18, 2024
News Daily News High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low Michael O'Riordan November 13, 2024
News Features GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix? Todd Neale November 13, 2024
News Conference News HFSA 2024 FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone? Michael O'Riordan October 02, 2024
News Daily News Hypertension Control in the US Still Has a Long Way to Go Todd Neale September 12, 2024
News Conference News ESC 2024 SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients Michael O'Riordan September 02, 2024
News Conference News ESC 2024 FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients Michael O'Riordan September 01, 2024
News Conference News ESC 2024 Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events Michael O'Riordan September 01, 2024